AAPS gives us a great opportunity to share our deep scientific and engineering research and discuss with clients and peers how our collective technologies can be used to tackle the drug-development obstacles facing the industry.
Bend, OR (PRWEB) November 05, 2013
Bend Research Inc., a part of Capsugel’s Dosage Form Solutions business, announced a full schedule of events at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition Nov. 10-14 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
“This will be our sixth time exhibiting at the AAPS Annual Meeting and Exposition and we are thrilled to be back,” said Jim Nightingale, president of Bend Research. “Together with Capsugel Dosage Form Solutions (DFS), we are excited about our broad technology offering in bioavailability enhancement, modified release, inhalation, and other key areas. AAPS gives us a great opportunity to share our deep scientific and engineering research and discuss with clients and peers how our collective technologies can be used to tackle the drug-development obstacles facing the industry.”
Bend Research will participate in a number of technical events during the meeting.
Dan Dobry will give a presentation during a symposium titled “Amorphous Dispersions as a Means to Increase Bioavailability in Preclinical and Clinical Studies,” at 1:30 p.m. CST Nov. 11. Dobry also will participate in an open forum, with a talk titled “Collaborative Development and Commercialization of a Controlled Release Microsphere Technology” at noon CST Nov. 14.
Mike Morgen, Ph.D. will be presenting “Formulating to Overcome PK Challenges in Early Preclinical Models” in a mini-symposium at 9 a.m. CST Nov. 13.
At 7 p.m. CST Nov. 13, Rod Ketner, Ph.D., will present “Generation of Reactive Species during Drug Product Manufacturing – An Overview” in an open forum.
Bend Research scientists will also present four posters during the meeting.
- “Small Scale Manufacture of Modified Release Coated Beads for Preclinical Drug Discovery Research,” presented by Mike Morgen, Ph.D., at 1:30 p.m. CST Nov. 12
- “Impact of Roller Compaction and Milling Parameters on Granulation and Tablet Attributes for a Low Dose Amorphous Spray Dried Dispersion Based Formulation,” presented by Randy Wald, R.Ph., at 1:30 p.m. CST Nov. 12
- “Heated Spray Drying Process and Formulation Development for A Spray-Dried Dispersion,” presented by Corey Bloom, Ph.D., at 1:30 p.m. CST Nov. 13
- “Impact of Polymer Composition and Properties on the Dissolution Characteristics of HPMCAS Based Spray-Dried Dispersions,” presented by Mike Morgen, Ph.D., at 1:30 p.m. CST Nov. 13
Bend Research will be located at Booth 533 throughout the meeting and will host a “Cowboy Cocktail Hour” from 4 to 6 p.m. Nov. 11 and 12. Cocktail hour attendees will have the opportunity to participate in a drawing for a Nike+ FuelBand.
Note: To schedule an interview with Bend Research experts or for any other press inquiry, please contact Phoenix Barringer at 541-382-4100.
About Bend Research
For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company’s ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding. Bend Research is a leader in novel formulations, including spray-dried dispersion (SDD) and hot-melt extrusion (HME) formulations, as well as controlled-release, inhalation, and biotherapeutics technologies.
Bend Research is now part of Capsugel’s Dosage Form Solutions business unit headquartered in Morristown, N.J., providing access to additional technologies, R&D capabilities, and global manufacturing infrastructure for the advancement of client compounds from concept through clinical to commercial manufacture.
Bend Research has more than 250 employees based in six state-of-the-art facilities in Bend, Ore., USA, and is part of the global Capsugel network of 3,100 employees.
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry. The company’s Hard Capsule business offers customers the broadest portfolio of gelatin, vegetarian, and other specialized capsule technologies. Capsugel’s Dosage Form Solutions (DFS) business utilizes an array of proprietary technologies and specialized manufacturing capabilities to solve customers’ most pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. The company's fast-to-clinic program streamlines product development from pre-formulation through clinical and commercial supply for finished dosage forms. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries. For additional information, visit http://www.capsugel.com.